ArticleJAMA network open2019

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.

Lelia Maria de Almeida Carvalho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.